SAN FRANCISCO, March 5 /PRNewswire/ - Aesthera today announced several new launches at the upcoming 67th annual meeting of the American Academy of Dermatology in San Francisco, CA.
Aligned with the company's strategic imperative to stay at the forefront of innovations in skin management, the launches will focus on the company reinforcing its leadership as the premier device based solution for acne as well as the development and commercialization of innovative technological solutions for high demand patient procedures.
Strengthening Position as Leading Acne Treatment
Strengthening its leadership position as a premier treatment in the battle against acne, Aesthera announced its latest peer reviewed clinical paper titled "Treatment of Acne with Photopneumatic Therapy," by Tina S. Alster MD et al which is published in the March 2009 issue of the Journal of Drugs and Dermatology.
The paper studies the clinical efficacy of Photopneumatic Therapy for the treatment of mild to severe facial acne.
"Our study noted greatest improvement in patients with severe acne. We are pleased with treatment outcomes, especially for severe acne," said study co-investigator Dr. Alster.
The study was performed using Aesthera's ISOLAZ system, the only FDA cleared device for the treatment of Comedonal and Pustular Acne.
Profusion Skin Therapy for Acne, Skin Rejuvenation and Body Tightening
Aesthera will launch Profusion -(Pro=Professional and Fusion=Combination) a breakthrough skin therapy that combines the proven clinical benefits of Photopneumatic light treatments with the delivery of Aesthera's proprietary skincare to symbiotically enhance skin treatment outcomes for acne, skin rejuvenation and body tightening.
"Profusion's novel mechanism has tremendous therapeutic potential for innovative new applications. We are very excited about its clinical potential," says Vic Narurkar, MD, Chair of Dermatology at the California Pacific Medical Center (CPMC) in San Francisco, CA.
"Profusion Skin Therapy is the fastest growing procedure in our practice. We routinely perform it in combination with the majority of skin treatments we offer," he adds. New applications of the technology include body tightening and skin lightening.
Additionally, Aesthera will release results of a multi-year scientific collaboration with the University of California at Riverside on Profusion Skin Therapy.
"Our collaboration with the UC Riverside team reflects our commitment to basing all our treatment solutions on solid science," says Robert Anderson, PhD, Co-Founder and Chief Technical Officer of Aesthera.
"We are very excited about expanding the commercial applications of Profusion Skin Therapy and are working on future applications of this novel technology," he added.
Innovative Body Tightening Technology
Moving beyond existing frameworks that address and treat body tightening, shaping and contouring Aesthera will be previewing a revolutionary approach to body tightening technology.
The company's innovative body tightening platform (pending FDA clearance) will utilize a unique delivery mechanism and state of the art applicator that allows for high treatment precision and focused energy delivery.
The patient benefits of Aesthera's unique solution will be fast, painless, and extremely precise treatments.
"Our continuous development and commercialization of solutions reflects our commitment to growing and strengthening our leadership position in the dermatology market," said Alon Maor, Aesthera's President & CEO.
In addition, to the above launches, Aesthera's technology will be included in over 11 podium presentations by thought leaders in dermatology.
For a complete list of podium presentations, or for more information on Profusion Skin Therapy or Isolaz Light Treatments, visit www.AESTHERA.Com, www.ISOLAZ.com, call 877.275.4779, or email WeListen@AESTHERA.com.
About Photopneumatic Technology
Photopneumatic Therapy, that powers the Isolaz and Isolaz Pro system, is a proprietary combination of pneumatic energy and broad band light.
Photopneumatic devices are the only laser or light based devices cleared for the treatment of inflammatory acne, comedonal acne and pustular acne.
They are also cleared for the treatment of mild to moderate inflammatory acne. Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless.
Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin.
Additionally, Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless.
Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin.
Additionally, Photopneumatic Therapy is also cleared for the treatment of benign vascular and pigmented lesions and hair removal.
About Aesthera Corporation
Aesthera (www.AESTHERA.com) develops, manufactures and markets light-based aesthetic treatment systems - the Isolaz and Isolaz Pro platforms - based on proprietary Photopneumatic technology.
Clinically proven to be pain-free and up to seven times faster than currently available light-based aesthetic systems, Aesthera's revolutionary systems combine the proven properties of therapeutic light with gentle pneumatic energy to more effectively work on dermal and epidermal skin targets.
